About Hyloris
Hyloris is a company based in Minneapolis (United States) founded in 2014.. Hyloris has raised $16.29 million across 1 funding round from investors including Nomainvest, Noshaq and Saffelberg Investments. The company has 14 employees as of December 31, 2021. Hyloris offers products and services including Maxigesic IV and Sotalol IV. Hyloris operates in a competitive market with competitors including Portola Pharma, Cellino, Arrakis Therapeutics, Flexion Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Minneapolis, United States
- Employees 14 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.29 M (USD)
in 1 rounds
-
Latest Funding Round
$16.29 M (USD), Series B
Apr 30, 2020
-
Investors
Nomainvest
& 2 more
-
Employee Count
14
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hyloris
Hyloris offers a comprehensive portfolio of products and services, including Maxigesic IV and Sotalol IV. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Intravenous drug for pain relief in medical settings.
Intravenous treatment for heart rhythm disorders.
Unlock access to complete
Funding Insights of Hyloris
Hyloris has successfully raised a total of $16.29M through 1 strategic funding round. The most recent funding activity was a Series B round of $16.29 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $16.3M
-
First Round
First Round
(30 Apr 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Series B - Hyloris | Valuation | Noshaq , Saffelberg Investments |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hyloris
Hyloris has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Nomainvest, Noshaq and Saffelberg Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Noel family investments are managed by this family office.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hyloris
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hyloris
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hyloris Comparisons
Competitors of Hyloris
Hyloris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, Cellino, Arrakis Therapeutics, Flexion Therapeutics and Tenaya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hyloris
Frequently Asked Questions about Hyloris
When was Hyloris founded?
Hyloris was founded in 2014 and raised its 1st funding round 6 years after it was founded.
Where is Hyloris located?
Hyloris is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Who is the current CEO of Hyloris?
Stijn Van Rompay is the current CEO of Hyloris.
Is Hyloris a funded company?
Hyloris is a funded company, having raised a total of $16.29M across 1 funding round to date. The company's 1st funding round was a Series B of $16.29M, raised on Apr 30, 2020.
How many employees does Hyloris have?
As of Dec 31, 2021, the latest employee count at Hyloris is 14.
What does Hyloris do?
Hyloris was founded in 2014 and is based in Minneapolis, United States. Focus is placed on pharmaceutical development for rare and orphan conditions. The pipeline includes Sotalol IV for arrhythmia, P-004 for inherited bleeding disorders, P-002 for pain management, and P-006 for oral mucositis. Generics such as Podofilox for vaginal warts and Dinoprostone for labor induction are also pursued in the sector.
Who are the top competitors of Hyloris?
Hyloris's top competitors include Flexion Therapeutics, Tenaya Therapeutics and Cellino.
What products or services does Hyloris offer?
Hyloris offers Maxigesic IV and Sotalol IV.
Who are Hyloris's investors?
Hyloris has 3 investors. Key investors include Nomainvest, Noshaq, and Saffelberg Investments.